Articles tagged "Hepatitis C"

2016 American Transplant Congress
Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.
J. Wiegel, T. Egbuka.
Pharmacy, Oregon Health & Science University, Portland, OR.
Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or…
2016 American Transplant Congress
Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant.
E. Verna,¹ J. Levitsky,² J. O'Leary,³ N. Bzowej,⁴ D. Moonka,⁵ R. Hyland,⁶ D. Brainard,⁶ J. McHutchison,⁶ N. Terrault.⁷
¹Columbia Univ., NY; ²Northwestern Univ., Chicago; ³Baylor Univ., Dallas; ⁴Ochsner Clinical Foundation, New Orleans; ⁵Henry Ford Hospital, Detroit; ⁶Gilead Sciences, Foster City; ⁷UCSF, San Francisco.
Background:The optimal timing and duration of DAA therapy in HCV patients undergoing liver transplant(LT) is unknown. CRUSH-C is an open-label, Phase 2 study evaluating the…
2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹
¹University of Colorado, Aurora, CO; ²Baylor University Medical Center, Dallas, TX; ³Gilead Sciences, Inc., Foster City, CA.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…
2016 American Transplant Congress
Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.
A. Morales,¹ M. Singla,² H. Greenwald,¹ S. Robertazzi,¹ C. Rodigas,¹ V. Washington,¹ R. Satoskar,¹ C. Smith.¹
¹MedStar Transplant Institute, Georgetown University Hospital, Washington, DC; ²Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, MD.
The purpose of this study was to assess the effect of hepatitis C virus (HCV) eradication with sofosbuvir based regimens on glycemic and lipid control…
2016 American Transplant Congress
Decline of HCV RNA and Core Antigen: Predictors of Achieving SVR in Transplant Recipients Undergoing DAA-Therapy.
S. Pischke,³ V. Proske,¹ S. Polywka,⁴ M. Lütgehetmann,⁴ M. Lang,¹ S. Stauga,¹ L. Fischer,¹ A. Lohse,³ B. Nashan,² M. Sterneck.¹
¹University Transplant Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; ²Department of Hepatobiliary Surgery and Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany; ³Department of Medicine, University Hospital Hamburg Eppendorf, Hamburg, Greece; ⁴Department of Microbiology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Background:DAA-treatment of hepatitis C virus (HCV) re-infections in orthotopic liver transplant (OLT) recipients has been demonstrated to be safe and effective in controlled studies, but…
2016 American Transplant Congress
Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.
T. Pastrana-Camacho,¹ M. Bradley,¹ H. Winters,¹ S. Black,² K. Porter,³ K. Mumtaz.⁴
¹Pharmacy, The Ohio State University-Wexner Medical Center, Columbus, OH; ²Department of Surgery, The Ohio State University-Wexner Medical Center, Columbus, OH; ³Center for Biostatistics, The Ohio State University-Wexner Medical Center, Columbus, OH; ⁴Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The Ohio State University-Wexner Medical Center, Columbus, OH.
Background: The literature is growing in the area of safety, efficacy and tolerability of sofosbuvir (SOF)- based antivirals therapy (AVT) in recurrent hepatitis C virus…
2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…
2016 American Transplant Congress
Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.
A. Ajlan,¹ A. Aljedai,¹ H. Elsiesy,² D. Alkortas,¹ R. Alarieh,² W. Alhumodi,² D. Broring,² M. Alsebayel,² F. Aba Alkhail.²
¹Pharmaceutical Care, KFSHRC, Riyadh, Saudi Arabia; ²Liver and Small Bowel Transplant, KFSHRC, Riaydh, Saudi Arabia.
This is an open label, prospective, interventional cohort study conducted at a tertiary referral center. The primary end point is SVR12 in patients treated with…
2016 American Transplant Congress
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.
M. Lubetzky,¹ S. Chun,¹ A. Joelson,¹ E. Akalin,¹ P. Gaglio,² G. DeBoccardo.¹
¹Transplantation, Albert Einstein College of Medicine, Bronx, NY; ²Hepatology, Columbia Universtiy, New York, NY.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…
2016 American Transplant Congress
Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.
A. Weick, O. Sadiq, S.-M. Jafri, D. Moonka.
Henry Ford Hospital, Detroit, MI.
Objectives:Evaluate outcomes of Ledipasvir-Sofosbuvir based hepatitis C therapy in liver transplant patients at a single center.Methods:All post-liver transplant patients started on Ledipasvir-Sofosbuvir therapy between January…